Analysis of the medical insurance status and efficacy of sotoracib (AMG510)

Sotorasiib (AMG510), an innovative drug targeting KRAS G12C mutated non-small cell lung cancer (NSCLC), has been receiving accelerated approval in the United States in 2019. Although it has been approved for use in specific patient groups in more than 40 countries around the world, in my country, because the original drug of sotorasibu has not yet been approved by the National Medical Products Administration, it is not currently included in the scope of medical insurance.

Sotorasiib, with its ability to specifically and irreversibly inhibitKRAS G12C, provides a new treatment option for patients with advanced non-small cell lung cancer. In the CodeBreaK Phase 100 study, the drug demonstrated encouraging efficacy in patients with KRAS G12C-mutated advanced non-small cell lung cancer. Specifically, the objective response rate (ORR) reached 37%, the median duration of response (DOR) was 11.1 months, the median progression-free survival (PFS) was 6.8 months, and the median overall survival (OS) reached 12.5 months. This data proves that sotoraxib brings significant survival benefits to patients while maintaining a controllable safety profile.

In an analysis of more than 2 years of follow-up data, nearly one-quarter of patients with advanced KRAS G12C-mutated non-small cell lung cancer who received sotoraxib achieved long-term benefit with almost no late treatment-related toxicity. Although some side effects may occur during drug use, such as diarrhea, nausea, vomiting, etc., these reactions are controllable in most cases, and some patients may need to adjust the drug dosage or temporarily discontinue the drug according to the doctor's advice.

The efficacy and safety data of sotoraxib provide strong support for its application in the treatment of advanced non-small cell lung cancer, and also lay the foundation for exploring its potential role in early treatment. However, for Chinese patients, since the drug has not yet been launched in the country and included in medical insurance, its accessibility is still a big challenge.